Gail S. Page Joins Chembio Diagnostics Board of Directors
July 06 2017 - 8:50AM
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in
point-of-care (POC) diagnostic tests for infectious
diseases, today announced that Gail S. Page has joined
the Company’s Board of Directors. “Gail is an accomplished
executive with extensive experience in the
diagnostics industry. Her impressive record in product
development, commercialization, operations, healthcare finance, and
strategic transactions strengthens our Board,” stated Katherine L.
Davis, Chair of Chembio’s Board of Directors. “Chembio is
developing a range of point-of-care diagnostic tests to address a
number of the world’s most serious sexually transmitted and fever
diseases. We are also growing our global commercial organization.
This is a pivotal time for Chembio and the Board of Directors will
benefit from Gail’s insight, judgment and counsel.”
Ms. Page has spent her entire career in health care with a focus
on diagnostics and emerging technologies. In January 2013, Ms.
Page founded Vineyard Investment Advisors (VIA), through
which she works with entrepreneurs, businesses, and universities to
transform their ideas into products and services. Prior
to VIA, Ms. Page served as the President, CEO and a
Director of Vermillion, Inc., a healthcare company
focused on developing and commercializing novel diagnostic blood
tests. As President and CEO, Ms. Page directed Vermillion's
repositioning to highlight the progressive nature of its
pipeline, successfully raised over $100M in funding, developed and
commercially launched the OVA1® Test, which was the
first FDA-cleared blood test to help diagnose ovarian cancer,
and engaged Quest Diagnostics as an equity and commercial
partner.
In the years preceding Vermillion, Ms. Page served as Executive
Vice President and Chief Operating Officer at Luminex, and as Sr.
Vice President at Roche Biomedical / Laboratory Corporation of
America (LabCorp), during which time her team launched
approximately 300 innovative tests, including a suite of HIV and
infectious disease assays. Ms. Page’s current board appointments
include Sword Diagnostics, Inc., Consortia Health Holdings (Chair
and Co-founder), and NxPrenatal, Inc., for which she serves as
Executive Chair. Ms. Page earned a Bachelors of
Science in Medical Technology from the University of
Florida, and completed an executive management program at the
Kellogg School in Chicago.
“Throughout my career, I have been privileged to work with
exceptional entrepreneurs and organizations committed to the
development and commercialization of
cutting-edge healthcare technologies,” stated Gail S.
Page. “I believe that Chembio’s DPP® technology is at
the forefront of the next generation of rapid, point-of-care,
diagnostic testing, and that Chembio's innovative products such as
its DPP® HIV-Syphilis Assay and its DPP® Fever Panel,
which address many of the most serious global infectious diseases,
have the potential to significantly improve treatment through rapid
and accurate diagnosis. I am very pleased to offer my experience to
Chembio as it pursues its development and global
commercialization goals.”
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and
markets proprietary rapid diagnostic tests in the growing $8.0
billion point-of-care testing market. Chembio markets each of
its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay, and SURE
CHECK® HIV 1/2 Assay, with these Chembio brand names, in the
U.S. and internationally, both directly and through third-party
distributors.
Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has
significant advantages over lateral-flow technologies. This
technology is providing Chembio with a significant pipeline of
business opportunities for the development and manufacture of new
products.
Headquartered in Medford, NY, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department
of Agriculture (USDA), and is certified for the global market under
the International Standards Organization (ISO) directive 13485.
Each of Chembio Diagnostic Systems, Inc. and RVR Diagnostics Sdn
Bhd is a wholly-owned subsidiary of Chembio Diagnostics,
Inc. For more information, please
visit: www.chembio.com.
Forward-Looking Statements
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act
of 1933, as amended. Forward-looking statements include statements
regarding the intent, belief or current expectations of the Company
and its management. Such statements, which are estimates only,
reflect management's current views, are based on certain
assumptions, and involve risks and uncertainties. Actual results,
events, or performance may differ materially from the above
forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not
limited to Chembio's ability to obtain additional financing and to
obtain regulatory approvals in a timely manner, as well as the
demand for Chembio's products. Chembio undertakes no obligation to
publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any
change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated
events. Factors that may impact Chembio's success are more fully
disclosed in Chembio's most recent public filings with the U.S.
Securities and Exchange Commission.
Contacts:
Chembio Diagnostics
Susan Norcott
(631) 924-1135, ext. 125
snorcott@chembio.com
Vida Strategic Partners (investor relations)
Stephanie C. Diaz
(415) 675-7401
sdiaz@vidasp.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024